Abstract:ABSTRACT In the context of pharmacogenomics, whole genome sequencing provides a powerful approach for identifying correlations between response variability to specific drugs and genomic polymorphisms in a population, in an unbiased manner. In this study, we employed whole genome sequencing of DNA samples from patients showing extreme response (n=72) and non-response (n=27) to the antiepileptic drug levetiracetam, in order to identify genomic variants that underlie response to the drug. Although no common SNP (MAF>5%) crossed the conventional genome-wide significance threshold of 5×10 −8 , we found common polymorphisms in genes SPNS3, HDC, MDGA2, NSG1 and RASGEF1C , which collectively predict clinical response to levetiracetam in our cohort with ∼91% predictive accuracy (∼94% positive predictive value, ∼85% negative predictive value). Among these genes, HDC, NSG1, MDGA2 and RASGEF1C are potentially implicated in synaptic neurotransmission, while SPNS3 is an atypical solute carrier transporter homologous to SV2A , the known molecular target of levetiracetam. Furthermore, we performed gene- and pathway-based statistical analysis on sets of rare and low-frequency variants (MAF<5%) and we identified associations between genes or pathways and response to levetiracetam. Our findings include a) the genes PRKCB and DLG2 , which are involved in glutamatergic neurotransmission, a known target of anticonvulsants, including levetiracetam; b) the genes FILIP1 and SEMA6D , which are involved in axon guidance and modelling of neural connections; and c) pathways with a role in synaptic neurotransmission, such as WNT5A-dependent internalization of FZD4 and disinhibition of SNARE formation . Targeted analysis of genes involved in neurotransmitter release and transport further supports the possibility of association between drug response and genes NSG1 and DLG2 . In summary, our approach to utilise whole genome sequencing on subjects with extreme response phenotypes is a feasible route to generate plausible hypotheses for investigating the genetic factors underlying drug response variability in cases of pharmaco-resistant epilepsy. AUTHOR SUMMARY Levetiracetam (LEV) is a prominent antiepileptic drug prescribed for the treatment of both focal and generalised epilepsy. The molecular mechanism mediating its action is not well understood, but it involves the modulation of synaptic neurotransmition through binding to the synaptic vesicle glycoprotein SV2A. Identifying genomic polymorphisms that predict response to the drug is important, because it can help clinicians prescribe the most appropriate treatment in a patient-specific manner. In this study, we employed whole genome sequencing (WGS) of DNA samples from extreme responders or non-responders to LEV and we identified a small group of common variants, which successfully predict response to the drug in our cohort. These variants are mostly located in genes implicated in synaptic function. Furthermore, we identified significant associations between clinical response to LEV and low-frequency variants in genes and pathways involved in excitatory neurotransmission or in the moulding of neural networks in the brain. Our approach to utilise WGS on subjects with extreme response phenotypes is a feasible route to generate plausible hypotheses on the genomic basis of pharmaco-resistant epilepsy. We expect that the rapidly decreasing cost of WGS will allow conducting similar studies on a larger scale in the near future.

No Major Role of Common SV2A Variation for Predisposition or Levetiracetam Response in Epilepsy.

Whole genome sequencing identifies putative associations between genomic polymorphisms and clinical response to the antiepileptic drug levetiracetam

A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam

Testing Association of Rare Genetic Variants with Resistance to Three Common Antiseizure Medications.

Efficacy of levetiracetam in STXBP1 encephalopathy with different phenotypic and genetic spectra

SCN1A and SCN2A Polymorphisms Are Associated with Response to Valproic Acid in Chinese Epilepsy Patients

Role of Common Genetic Variants for Drug-Resistance to Specific Anti-Seizure Medications

Effect of SCN1A and SCN2A gene polymorphisms on the efficacy of valproic acid treatment in Chinese children with epilepsy

Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A

Genetic Predictors of the Maximum Doses Patients Receive During Clinical Use of the Anti-Epileptic Drugs Carbamazepine and Phenytoin

Effects of SCN1A and SCN2A Polymorphisms on Responsiveness to Valproic Acid Monotherapy in Epileptic Children

Polymorphisms of ABAT, SCN2A and ALDH5A1 May Affect Valproic Acid Responses in the Treatment of Epilepsy in Chinese.

Population Pharmacokinetics of Valproic Acid in Epileptic Children: Effects of Clinical and Genetic Factors.

Assessing the role of rare genetic variants in drug-resistant, non-lesional focal epilepsy.

Pharmacogenetic and Case-Control Study on Potassium Channel Related Gene Variants and Genetic Generalized Epilepsy

Levetiracetam-Induced Cutaneous Adverse Drug Reactions Were Not Associated with Hla Genes in A Small Sample of Chinese Patients with Epilepsy

Levetiracetam Administration is Correlated with Lower Mortality in Patients with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes: a Retrospective Study

Levetiracetam modulates brain metabolic networks and transcriptomic signatures in the 5XFAD mouse model of Alzheimer's disease

Association of single nucleotide polymorphisms of SLCO1 A2 , SLCO2 B1 and SLCO1 B1 genes with the effectiveness of valproic acid in epileptic patients

Randomized-controlled Trials of Levetiracetam As an Adjunctive Therapy in Epilepsy of Multiple Seizure Types

Genomic and Clinical Predictors of Lacosamide Response in Refractory Epilepsies